In vivo最新文献

{"title":"Glatiramer Acetate Reduces Risk of Cardiovascular Disease and Myocardial Infarction.","authors":"Steven Lehrer, Peter H Rheinstein","doi":"10.21873/invivo.14001","DOIUrl":"10.21873/invivo.14001","url":null,"abstract":"<p><strong>Background/aim: </strong>The aim of the present study was to investigate on the repurposing of glatiramer acetate (GA), a drug traditionally used to treat multiple sclerosis, as well as explore GA potential to treat cardiac ischemia in rodent models. It has been shown that GA exerts immunomodulatory effects that reduced inflammation and increased repair of heart tissue following myocardial infarction (MI) in mice and rats. GA has been shown to enhance cardiac function by promoting angiogenesis, reducing scar tissue, and protecting cardiomyocytes from ischemic damage.</p><p><strong>Materials and methods: </strong>Risteys/FinnGen and MedWatch/OpenVigil data were used to assess the effects of GA on the heart.</p><p><strong>Results: </strong>There was significantly less ischemic heart disease (p<0.001, Fisher's exact test) and cardiovascular disease (p<0.001) in 457 subjects with MS who used GA in Risteys/FinnGen. Analysis of MedWatch/OpenVigil data showed a significantly reduced risk of acute MI in individuals using GA, with a proportional reporting ratio (PRR) of 0.101, indicating statistical significance at the 95% confidence level. Additionally, analysis of MedWatch/OpenVigil data indicated a decreased risk of cardiovascular disease in GA users, with a PRR of 0.345, reaching statistical significance at the 95% confidence level.</p><p><strong>Conclusion: </strong>Despite rare adverse cardiovascular side-effects and given its established safety profile, GA shows promise as a novel treatment option for heart disease. Further studies could lead to an important new use of GA especially in patients who do not receive tissue plasminogen activator within the first few hours following an MI.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2066-2072"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Thyroid Dose on Radiation-induced Hypothyroidism in Early Glottic Cancer Patients Undergoing Volumetric Modulated Arc Therapy.","authors":"Hae Jin Park, Taeryool Koo, Kwang-Ho Cheong, Me Yeon Lee, Hyeon Kang Koh, Younghee Park","doi":"10.21873/invivo.14038","DOIUrl":"10.21873/invivo.14038","url":null,"abstract":"<p><strong>Background/aim: </strong>To evaluate the incidence of radiation-induced hypothyroidism (RIHT) and its association with thyroid dose in patients undergoing volumetric modulated arc therapy (VMAT) for early glottic cancer.</p><p><strong>Patients and methods: </strong>We retrospectively reviewed 23 patients with early glottic cancer who received VMAT between 2018 and 2023. All included patients had normal baseline thyroid function tests. RIHT was defined as an increase in thyroid-stimulating hormone levels with or without a decrease in free-T4 or T3 levels. Dose-volume parameters (DVPs) of the thyroid gland, including mean dose and the relative thyroid volume receiving at least 10-60 Gy (V_10Gy-V_60Gy), were analyzed for correlation with RIHT.</p><p><strong>Results: </strong>The median follow-up time was 36.4 months, during which all patients survived. The 1-year and 3-year local failure-free survival rates were 91.3% and 82.4%, respectively. The median mean dose was 25.2 Gy. RIHT developed in five patients (21.7%), with a median onset time of 16.7 months after VMAT. Among them, one patient received thyroid hormone therapy. Among the DVPs, V_10Gy>70% was significantly associated with a higher risk of RIHT. The 2-year rates of RIHT were 6.2% in patients with V_10Gy≤70% and 44.4% in patients with V_10Gy>70% (<i>p</i>=0.006). Age and underlying diseases were not associated with RIHT.</p><p><strong>Conclusion: </strong>A considerable proportion of patients developed RIHT after VMAT for early glottic cancer. The thyroid gland should be recognized as an important organ at risk. For VMAT planning, V_10Gy may serve as a useful optimization constraint.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2397-2404"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223635/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of MMP-11 Genotypes With Colorectal Cancer in Taiwan.","authors":"Tao-Wei Ke, Ming-Hsien Wu, Ying-Jing Chen, Te-Cheng Yueh, Hou-Yu Shih, Yu-Chen Chang, Yun-Chi Wang, Chia-Wen Tsai, DA-Tian Bau, Wen-Shin Chang","doi":"10.21873/invivo.13988","DOIUrl":"10.21873/invivo.13988","url":null,"abstract":"<p><strong>Background/aim: </strong>Matrix metalloproteinase-11 (MMP-11) is a member of the MMP enzyme family, known for its critical function in extracellular matrix turnover and tissue restructuring. This study aimed to investigate the potential associations between four <i>MMP-11</i> single-nucleotide polymorphisms (SNPs)-rs738791, rs2267029, rs738792, and rs28382575-and colorectal cancer (CRC) susceptibility in a Taiwanese cohort.</p><p><strong>Materials and methods: </strong>A total of 362 CRC patients and non-cancer controls were genotyped using the restriction fragment length polymorphism method. The distribution of genotypes and alleles was assessed, and conformity to Hardy-Weinberg equilibrium was confirmed for all examined loci (<i>p</i>>0.05).</p><p><strong>Results: </strong>No statistically significant differences were observed in the genotype frequencies of <i>MMP-11</i> rs738791, rs2267029, rs738792, or rs28382575 between CRC patients and healthy controls (<i>p</i> for trend=0.8640, 0.6638, 0.3275, and 0.8051, respectively). Allelic analyses further revealed lack of associations with CRC risk regarding rs738791 T allele (OR=1.06, 95%CI=0.85-1.32, <i>p</i>=0.6550), rs2267029 A allele (OR=1.11, 95%CI=0.88-1.40, <i>p</i>=0.4073), rs738792 C allele (OR=1.02, 95%CI=0.81-1.29, <i>p</i>=0.9055), and rs28382575 C allele (OR=1.17, 95% CI=0.67-2.04, <i>p</i>=0.6718). Interestingly, individuals carrying the CT or TT genotypes of rs738791 were more likely to present with larger tumor sizes (≥5 cm, <i>p</i>=0.0298) and absence of metastasis (<i>p</i>=0.0218). Moreover, the AG or AA genotypes of rs2267029 were significantly associated with advanced clinical stages (III-IV, <i>p</i>=0.0007).</p><p><strong>Conclusion: </strong>Although the investigated <i>MMP-11</i> polymorphisms were not associated with CRC susceptibility, the rs738791 and rs2267029 variant genotypes may serve as potential prognostic biomarkers.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"1891-1901"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of Catalyst⁺ HD System Under Varying Postural, Couch Angle, and Isocenter Conditions in Intracranial Stereotactic Irradiation.","authors":"Tenyoh Suzuki, Shingo Ohira, Yusaku Imanishi, Yukari Yamaguchi, Yuki Nozawa, Takeshi Ohta, Takuya Hayashi, Masanari Minamitani, Atsuto Katano, Hideomi Yamashita, Keiichi Nakagawa","doi":"10.21873/invivo.13991","DOIUrl":"10.21873/invivo.13991","url":null,"abstract":"<p><strong>Background/aim: </strong>This study assessed the positional detection accuracy of the Catalyst⁺ HD system for intracranial stereotactic irradiation (STI) under clinically relevant conditions, including variations in head posture, isocenter position, and couch angle.</p><p><strong>Materials and methods: </strong>An anthropomorphic head phantom was used to simulate three head postures, chin-up, neutral, and chin-down, each stabilized with a corresponding thermoplastic mask. Seven isocenter positions were defined: one central position and six offset positions, each 5 cm away in a cardinal direction. Treatment plans incorporated multiple couch angles (0°, 30°, 45°, 60°, and 90°). The Catalyst⁺ HD system's accuracy was evaluated by comparing its detected displacements to predefined shifts applied using a HexaPOD evo RT system. Translational shifts of ±3 mm and rotational shifts of ±2° were introduced. Statistical analysis was conducted using the Wilcoxon signed-rank test.</p><p><strong>Results: </strong>Under standard conditions (neutral posture, central isocenter, and 0° couch angle), the system demonstrated submillimeter accuracy (mean translational error: 0.08 mm; mean rotational error: 0.12°). Detection errors were significantly larger in the chin-up posture compared to the neutral posture (<i>p</i>=0.028). Similarly, a superior isocenter position resulted in considerably larger errors (<i>p</i>=0.026). A couch rotation of 30° led to a significant increase in error, whereas other couch angles maintained high precision.</p><p><strong>Conclusion: </strong>The Catalyst⁺ HD system exhibits high accuracy for intracranial STI under most tested conditions. However, to optimize performance and accuracy, configurations involving a chin-up posture or a superior isocenter position should be avoided.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"1924-1931"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying the Primary Tumor Site and Distinguishing False-positives in Patients With Elevated Serum Carcinoembryonic Antigen.","authors":"Hiroaki Satoh, Takumi Sakamoto, Yutaka Takahashi, Kunihiko Miyazaki, Satoshi Inagawa","doi":"10.21873/invivo.14035","DOIUrl":"10.21873/invivo.14035","url":null,"abstract":"<p><strong>Background/aim: </strong>Carcinoembryonic antigen (CEA) is a tumor marker that is frequently evaluated clinically for gastrointestinal and lung cancers. CEA is a glycoprotein antigen, and only the \"value\" measured by enzyme-linked immunosorbent assay is provided in the clinical setting. At present, no method has been established to indicate whether the value is a false-positive elevation or whether there is a primary cancer site. To obtain clues on how to identify the originating site in patients with cancer with high CEA levels and to identify CEA false-positives in healthy individuals, we conducted an exploratory study.</p><p><strong>Patients and methods: </strong>A pilot study was performed using the multivariate analysis method and principal component analysis-discriminant analysis on proteomic results obtained using liquid chromatography-mass spectrometry (LC/MS) in two patients with lung cancer, one patient with gastric cancer, and one healthy control individual.</p><p><strong>Results: </strong>No differences in specific proteins associated with high CEA levels were detected between lung and gastric cancers using LC/MS. Therefore, we performed statistical analysis using principal component analysis-discriminant analysis to determine whether there were differences in the protein signal patterns obtained using LC/MS. The results showed that the plots obtained for each patient and the healthy control were located in different quadrants of the four-quadrant matrix scatter plot.</p><p><strong>Conclusion: </strong>Our results suggest the possibility of visually differentiating the primary tumor site in patients with elevated CEA levels. This method may also help recognize false-positive CEA results.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2371-2376"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ifosfamide, Carboplatin, and Etoposide as Neoadjuvant Chemotherapy in Patients With Neurofibromatosis Type I-related Malignant Peripheral Nerve Sheath Tumors.","authors":"Junji Wasa, Hirohisa Katagiri, Hideki Murata, Shunichi Toki, Kan Ito, Mitsuru Takahashi","doi":"10.21873/invivo.14022","DOIUrl":"10.21873/invivo.14022","url":null,"abstract":"<p><strong>Background/aim: </strong>The role of chemotherapy for malignant peripheral nerve sheath tumors (MPNSTs) remains controversial, particularly in neurofibromatosis type 1 (NF1)-related MPNST (NF1-MPNST). This study aimed to assess the clinical outcomes of patients with NF1-MPNST who underwent curative treatment comprising neoadjuvant chemotherapy followed by wide resection.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed data from patients with NF1-MPNST who received preoperative chemotherapy. The regimen was ifosfamide 1.5 g/m² on days 1-3, carboplatin 400 mg/m² on day 3, and etoposide 100 mg/m² on days 1-3 (ICE). Radiographic response, overall survival, and toxicity were evaluated.</p><p><strong>Results: </strong>We analyzed data from 12 patients treated between 2005 and 2023. All patients received two to four courses of ICE without concomitant radiation therapy, with a median 20.4% (range=-14-63%) reduction in tumor size. According to the RECIST criteria, four patients had partial responses and eight had stable disease. The 5-year overall survival rate was 81.8%. The survival rate of patients with a partial response was 100%. Toxicities included myelosuppression, nausea, and general fatigue. Three patients received platelet transfusions. Three patients discontinued neoadjuvant chemotherapy because of patient preference.</p><p><strong>Conclusion: </strong>In this study, we achieved more favorable outcomes than those in previous studies. Neoadjuvant chemotherapy, which included the ICE regimen, not only resulted in tumor shrinkage in eight of 12 cases but also demonstrated a good prognosis when tumor shrinkage was achieved. These findings suggest that neoadjuvant chemotherapy with the ICE regimen may be a promising approach for managing NF1-MPNST.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2267-2276"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Adjuvant Chemotherapy Following Neoadjuvant Concurrent Chemoradiotherapy and Total Mesorectal Excision in Rectal Cancer.","authors":"Yu-Shih Liu, Jen-Kou Lin, Tzu-Chen Lin, Wei-Shone Chen, Shung-Haur Yang, Huann-Shenn Wang, Shih-Ching Chang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Jeng-Kai Jiang","doi":"10.21873/invivo.14027","DOIUrl":"10.21873/invivo.14027","url":null,"abstract":"<p><strong>Background/aim: </strong>This study investigated the efficacy of adjuvant chemotherapy (ACT) after total mesorectal excision (TME) for rectal cancer in patients who responded well to neoadjuvant concurrent chemoradiotherapy (nCCRT).</p><p><strong>Patients and methods: </strong>This retrospective study included patients with rectal cancer treated at Taipei Veterans General Hospital (2009-2017). Among 302 patients who underwent nCCRT and TME, 178 good responders [pathologic complete response (pCR), pT1, or pT2] were analyzed. Patients were grouped based on ACT administration. Primary outcomes included disease-free survival (DFS) and recurrence. Kaplan-Meier survival analysis and Cox proportional hazards regression were used to assess ACT efficacy.</p><p><strong>Results: </strong>The ACT group (n=96) had poorer baseline disease characteristics, including higher initial clinical T and N stages. However, recurrence rates did not differ significantly between ACT and non-ACT groups (23.2% <i>vs</i>. 17.7%, <i>p</i>=0.271). DFS curves showed no significant difference between ACT and non-ACT groups (<i>p</i>=0.360). Multivariable analysis confirmed that ACT was not significantly associated with DFS [adjusted hazard ratio (aHR)=0.76, 95% confidence interval (CI)=0.37-1.59]. However, the advanced surgical pT stage (pT3-pT4) was an independent predictor of recurrence (aHR=3.24, 95%CI=1.01-10.38, <i>p</i>=0.047).</p><p><strong>Conclusion: </strong>The role of ACT remains inconclusive after TME for rectal cancer in patients who respond well to nCCRT. Surgical pT stage, particularly pT3 and pT4, remain a significant predictor of recurrence, emphasizing its importance in risk stratification.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2311-2319"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NeuroD2 Modulates Hippocampal Neuronal Organization and Axon Guidance During Aging.","authors":"Merve Beker, Busenur Bolat, Bahar Sarikamis Johnson, Nilufer Ercin, Rabia Kalkan Cakmak, Sare B Kaya, Nail Besli, Ulkan Celik, Mustafa C Beker","doi":"10.21873/invivo.14000","DOIUrl":"10.21873/invivo.14000","url":null,"abstract":"<p><strong>Background/aim: </strong>Biological aging refers to the progressive deterioration of an organism's functions due to accumulated cellular and molecular damage. NeuroD2, a critical transcription factor, plays a crucial role in neuronal development and synaptic maturation. This study investigates the role of NeuroD2 in hippocampal neuron organization, focusing on hilar mossy cells during aging, and employs bioinformatics to identify NeuroD2 targets linked to cellular aging.</p><p><strong>Materials and methods: </strong>We used 21 adult C57Bl/6 mice, categorized into three age groups: young (2 months), old (12 months), and very old (24 months). Mice were administered BrdU intraperitoneally for three consecutive days, 10 days before euthanasia. The brains were harvested and analyzed using immunofluorescence, Western blotting, and quantitative real-time PCR to evaluate NeuroD2 expression and associated signaling pathways in hippocampal tissue. Additionally, bioinformatics analysis was performed using two open-access datasets (ProteomeXchange Consortium, Dataset identifier: PXD043352; Gene Expression Omnibus, GEO: GSE67539) and to explore potential interactions between NeuroD2 targets and biological aging components.</p><p><strong>Results: </strong>Our results revealed that NeuroD2 expression changed significantly with age and correlated with AKT signaling. Moreover, we identified a potential link between NeuroD2 activity and the AKT pathway, indicating NeuroD2's role in mitigating aging-related stress. Bioinformatics analysis identified 513 down-regulated and 638 up-regulated proteins, with NeuroD2 targets involved in axonal projection showing increased expression in older mice. Contrary to expectations, pathway enrichment analysis highlighted axon guidance molecules rather than oxidative stress markers.</p><p><strong>Conclusion: </strong>This study underscores NeuroD2's critical role in preserving hippocampal integrity and reveals molecular mechanisms underlying age-related neuronal changes. Our findings provide insights into the role of NeuroD2 in regulating key pathways during healthy aging, potentially mitigating the impacts of aging.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2050-2065"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Painful Angiomyoma of the Heel Region: A Rare Case Report.","authors":"Yi-Yen Tsai, Jeng-Wei Lu, Hao Yen, Chih-Chien Wang","doi":"10.21873/invivo.14049","DOIUrl":"10.21873/invivo.14049","url":null,"abstract":"<p><strong>Background/aim: </strong>Angiomyomas are rare benign smooth muscle tumors originating from the tunica media of blood vessel walls, most frequently affecting the lower extremities in middle-aged women.</p><p><strong>Case report: </strong>We report the case of a 51-year-old female with a six-month history of a painful, palpable mass in the right heel. Physical examination revealed a soft, mobile, and tender subcutaneous nodule. Ultrasound imaging identified a 0.5 cm well-defined hypoechoic lesion in the subcutaneous layer, without internal blood flow, initially suspected to be an epidermoid cyst or fibrous tumor. Surgical excision of the lesion was performed, and histopathological analysis revealed a well-encapsulated tumor consisting of spindle-shaped cells with eosinophilic cytoplasm and bland nuclei, accompanied by vascular components. Immunohistochemical staining confirmed positive expression of SMA, establishing the diagnosis of angiomyoma. The patient experienced an uneventful postoperative recovery.</p><p><strong>Conclusion: </strong>This case highlights the diagnostic challenges of angiomyomas, given their nonspecific clinical presentation and imaging findings. While magnetic resonance imaging may reveal characteristic features such as strong gadolinium enhancement, definitive diagnosis relies on histopathological evaluation. Clinicians should include angiomyoma in the differential diagnosis of painful subcutaneous masses in the foot and ankle, particularly in middle-aged women. Surgical excision remains the definitive diagnostic and therapeutic approach, with low recurrence rates reported.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2485-2488"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Anthracycline-cyclophosphamide Regimens and Docetaxel Monotherapy in Oral Mucositis Development.","authors":"Yoshitaka Saito, Tatsuhiko Sakamoto, Yoh Takekuma, Masato Takahashi, Tomohiro Oshino, Mitsuru Sugawara","doi":"10.21873/invivo.14021","DOIUrl":"10.21873/invivo.14021","url":null,"abstract":"<p><strong>Background/aim: </strong>We have previously reported that patients experiencing oral mucositis (OM) during anthracycline-cyclophosphamide treatment develop symptoms following subsequent docetaxel-containing chemotherapy for perioperative breast cancer therapy. However, the concomitant use of pertuzumab and trastuzumab with docetaxel has also been suggested as a significant risk factor for OM. This study aimed to further evaluate the direct relationship of OM with anthracycline-cyclophosphamide treatment and docetaxel monotherapy.</p><p><strong>Patients and methods: </strong>Patients with breast cancer who underwent anthracycline-cyclophosphamide treatment followed by docetaxel monotherapy as perioperative therapy (n=63) were divided into control and OM-experience groups based on the absence or presence of OM development during prior anthracycline-cyclophosphamide treatment, and retrospectively evaluated. The primary endpoint was the comparison of all-grade OM incidence in the first docetaxel cycle between the two groups. The incidence of OM and dysgeusia was also assessed across all treatment cycles.</p><p><strong>Results: </strong>The incidence of all-grade OM was 42.9% in the OM-experience group and 9.5% in the control group during the first cycle (<i>p</i>=0.006) and 47.6% and 11.9% across all treatment cycles (<i>p</i>=0.004), thereby achieving the primary endpoint. In contrast, the incidence of grade ≥2 OM in both settings was higher in the OM-experience group than in the control group, although the difference was not statistically significant (14.3% <i>vs</i>. 2.4%, <i>p</i>=0.10 for both settings). Moreover, the incidence of dysgeusia did not differ between the two groups.</p><p><strong>Conclusion: </strong>Patients exhibiting OM during prior anthracycline-cyclophosphamide treatment were significantly more likely to develop symptoms during subsequent docetaxel monotherapy for perioperative breast cancer therapy.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2259-2266"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}